GlobeNewswire: Zylö Therapeutics Contains the last 10 of 20 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T09:54:52ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/02/06/2824688/0/en/Zyl%C3%B6-s-Powered-by-Z-pods-technology-incorporated-into-BosleyMD-s-new-product-line.html?f=22&fvtc=4&fvtv=45426Zylö’s ‘Powered by Z-pods®’ technology incorporated into BosleyMD’s new product line2024-02-06T20:15:00Z<![CDATA[The breakthrough product, Revive+ Densifying Foam for hair growth, is now for sale at CVS]]>https://www.globenewswire.com/news-release/2023/10/03/2753638/0/en/Zyl%C3%B6-accepted-into-NYU-s-exclusive-Endless-Frontier-Labs-mentorship-program.html?f=22&fvtc=4&fvtv=45426Zylö accepted into NYU’s exclusive Endless Frontier Labs mentorship program2023-10-03T12:30:00Z<![CDATA[GREENVILLE, SC, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Zylö Therapeutics has been selected to join the Endless Frontier Labs (EFL) 2023-2024 cohort alongside 77 other startups. Over 1,400 companies applied, including over 350 life science companies, with only 26 chosen in each of the three tracks: life sciences, deep-tech, and digital tech. Over the next nine months, EFL mentors and NYU Stern MBA students will work with Zylö’s executive team to fine-tune Zylö strategies, craft an improved pitch deck, and set/achieve value-added objectives. Zylö hopes also to gain access to EFL’s connections in the investment community, as it considers spinning out the pharmaceutical side of its business.]]>https://www.globenewswire.com/news-release/2023/09/27/2750374/0/en/Zyl%C3%B6-s-Powered-By-Z-pod-Technology-Featured-in-Peer-Reviewed-Paper-Published-in-Experimental-Dermatology.html?f=22&fvtc=4&fvtv=45426Zylö’s ‘Powered By Z-pod’ Technology Featured in Peer-Reviewed Paper Published in Experimental Dermatology2023-09-27T12:30:00Z<![CDATA[Z-pods significantly improved outcomes in mouse model of cutaneous lupus]]>https://www.globenewswire.com/news-release/2023/05/31/2679716/0/en/Zyl%C3%B6-Receives-294-000-NIH-Phase-I-Grant-to-Advance-its-Cutaneous-Lupus-Program.html?f=22&fvtc=4&fvtv=45426Zylö Receives $294,000 NIH Phase I Grant to Advance its Cutaneous Lupus Program2023-05-31T17:00:00Z<![CDATA[Funds to be used to demonstrate efficacy in a new mouse model of cutaneous lupus]]>https://www.globenewswire.com/news-release/2022/09/16/2517652/0/en/Zyl%C3%B6-Receives-263-000-NIH-Phase-I-Grant-to-Develop-a-Topical-Viagra-for-ED.html?f=22&fvtc=4&fvtv=45426Zylö Receives $263,000 NIH Phase I Grant to Develop a Topical Viagra® for ED2022-09-16T12:30:00Z<![CDATA[Funds to be used to optimize a formulation and demonstrate comparable efficacy to oral Viagra]]>https://www.globenewswire.com/news-release/2022/08/19/2501626/0/en/Zyl%C3%B6-Receives-600-000-NIH-Phase-I-Grant-to-Develop-a-Novel-Therapeutic-to-Treat-Onychomycosis-Nail-Fungus.html?f=22&fvtc=4&fvtv=45426Zylö Receives $600,000 NIH Phase I Grant to Develop a Novel Therapeutic to Treat Onychomycosis (Nail Fungus)2022-08-19T13:00:00Z<![CDATA[Funds to be used to optimize a formulation and prepare for scale-up and IND-enabling studies]]>https://www.globenewswire.com/news-release/2022/06/03/2456036/0/en/Zyl%C3%B6-Therapeutics-Closes-5-225-Million-Series-B-Financing.html?f=22&fvtc=4&fvtv=45426Zylö Therapeutics Closes $5.225 Million Series B Financing2022-06-03T13:00:00Z<![CDATA[GREENVILLE, SC, June 03, 2022 (GLOBE NEWSWIRE) -- Zylö Therapeutics Inc., dedicated to developing a transformational drug-delivery platform, announced that it has raised $5.225 million in its Series B financing.]]>https://www.globenewswire.com/news-release/2021/11/10/2331641/0/en/Zyl%C3%B6-s-Erectile-Dysfunction-Product-Concept-Wins-Best-Abstract-Award.html?f=22&fvtc=4&fvtv=45426Zylö’s Erectile Dysfunction Product Concept Wins Best Abstract Award2021-11-10T14:00:00Z<![CDATA[The product concept uses patent-pending Z-pods™ to sustainably—for over an hour—release nitric oxide]]>https://www.globenewswire.com/news-release/2021/07/20/2265741/0/en/Zyl%C3%B6-Receives-1-700-000-NIH-Phase-II-Grant-to-Advance-Erectile-Dysfunction-Program-into-Human-Trials.html?f=22&fvtc=4&fvtv=45426Zylö Receives $1,700,000 NIH Phase II Grant to Advance Erectile Dysfunction Program into Human Trials2021-07-20T13:00:00Z<![CDATA[Funds to be used for scale-up, implementation of cGMP quality system, and pre-IND FDA meeting]]>https://www.globenewswire.com/news-release/2021/05/19/2232569/0/en/Zyl%C3%B6-and-Amifar-Laboratorios-Forge-Broad-Ranging-Partnership.html?f=22&fvtc=4&fvtv=45426Zylö and Amifar Laboratorios Forge Broad-Ranging Partnership2021-05-19T13:00:00Z<![CDATA[The Z-pod™ delivery system will further enhance the ‘Science of Beauty’]]>